載入中
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
前收盤價
US$3.94
+US$0.20 · +5.35%
盤中時間採用ET。市場資料可能有所延遲。
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
日內區間
目前US$3.94
52週區間
目前US$3.94
盤中時間採用ET。市場資料可能有所延遲。
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
日內區間
目前US$3.94
52週區間
目前US$3.94
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 31.7萬 USD | 208萬 USD |
| 銷貨成本 | 69.89萬 USD | — | — | 15.81萬 USD | 115.31萬 USD |
| 毛利 | −69.89萬 USD | — | — | 15.88萬 USD | 92.69萬 USD |
| 研究與開發 | 4204.85萬 USD | 4796.44萬 USD | 4162.4萬 USD | 3626.71萬 USD | 2654.1萬 USD |
| 銷售、一般及管理費用 | 1729.82萬 USD | 1607.8萬 USD | 1676萬 USD | 1560.7萬 USD | 827.2萬 USD |
| 營業費用 | 5867.71萬 USD | 6407.14萬 USD | 5841.29萬 USD | 5190.37萬 USD | 3481.3萬 USD |
| 利息收入 | 303.94萬 USD | 259.33萬 USD | 360.7萬 USD | 101.45萬 USD | 16.99萬 USD |
| 折舊和攤銷 | 35.38萬 USD | 38.51萬 USD | 35.21萬 USD | 27.73萬 USD | 15.91萬 USD |
| 營業利益 | −5937.6萬 USD | −6407.14萬 USD | −5841.29萬 USD | −5174.49萬 USD | −3388.61萬 USD |
| 淨利 | −5602.49萬 USD | −6103.66萬 USD | −5347.16萬 USD | −5051.36萬 USD | −3353.57萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI810.16萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM541.03萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF315.23萬0.00%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB166.84萬0.02%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO153.36萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC66.22萬0.05%13.17億 USD0.60%US$183+0.11%
ALPS Medical Breakthroughs ETFSBIO32.14萬0.17%1.91億 USD0.50%US$55.04+2.03%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM29萬0.25%1.17億 USD0.73%US$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
